Is buprenorphine patch more effective than standard oral medication in the management of post-tonsillectomy pain: a study on how people cope with the pain following the removal of tonsils

ISRCTN ISRCTN59862351
DOI https://doi.org/10.1186/ISRCTN59862351
EudraCT/CTIS number 2007-006117-16
Secondary identifying numbers Puranik 07/03/23
Submission date
24/10/2007
Registration date
16/04/2008
Last edited
21/04/2020
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Signs and Symptoms
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Mr Viswanath Puranik
Scientific

North West Wales NHS Trust
ENT Department
Ysbyty Gwynedd
Bangor
LL57 2PW
United Kingdom

Study information

Study designRandomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details provided in the interventions field to request a patient information sheet
Scientific titlePATCH Trial: Post-tonsillectomy Analgesia with buprenorphine Transdermal patCH: a prospective, randomised, phase IV, open label clinical trial to study the therapeutic use of buprenorphine 20 mg (Transtec®) matrix transdermal patch in the management of post-tonsillectomy pain in adults
Study acronymPATCH Trial
Study objectivesTo establish whether post-tonsillectomy analgesia using a transdermal patch has benefits over currently used oral analgesia, by comparatively measuring the clinical efficacy, the effective and perceived pain control, and the rate at which complications and adverse effects occur.
Ethics approval(s)North East Wales Research Ethics Committee (REC), 31/01/2008, ref: 07/WNo03/23
Health condition(s) or problem(s) studiedPost-tonsillectomy pain
InterventionArm A (interventional): will receive a 12 day supply of buprenorphine 20 mg (35 mg/h) (Transtec®) matrix transdermal patches (a total of four patches). Patients are required to replace the transdermal patch every three days.

Arm B (control): will receive a 12-day supply of codeine phosphate 30 mg/ paracetamol 500 mg (30/500/Solpadol®). Patients are required to take two tablets every four hours (p.r.n).

Total duration of treatment is 12 days. Final assessment and all data collected at day 10 (outpatient clinic), for both arms, no other follow-up.

Please use the following contact details to request a patient information sheet:
Dr. Rossela O. Stoicescu
Clinical Governance Officer (R&D Manager/Ethics Co-ordinator)
North Wales Clinical School - Clinical Academic Office
North West Wales NHS Trust
Ysbyty Gwynedd
Bangor, Gwynedd
LL57 2PW
Intervention typeDrug
Pharmaceutical study type(s)
PhasePhase IV
Drug / device / biological / vaccine name(s)Buprenorphine (Transtec®), codeine phosphate hemihydrate, paracetamol (Solpadol®)
Primary outcome measure1. Clinical efficacy: the buprenorphine : creatinine ratio
2. Perceived pain: measurements on the Visual Analogue Scale (VAS)
3. Coping strategies: the compounded prevalent strategy

All outcomes will be measured at day 10 of the intervention.
Secondary outcome measures1. Use (dose/frequency) of rescue medication
2. Readmission rate
3. Post-operative haemorrhage rate

All outcomes will be measured at day 10 of the intervention.
Overall study start date15/11/2007
Completion date30/10/2009

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants150 in each arm, 300 in total
Total final enrolment133
Key inclusion criteriaPatients undergoing tonsillectomy, who meet the following criteria:
1. Aged 18 to 50 years old, either sex
2. American Society of Anaesthesiologists (ASA) grade I and II: healthy patient, mild systemic disease with no functional limitation (e.g., well controlled hypertension [HTA])
Key exclusion criteria1. Age less than 18 or over 50 years
2. ASA grade III - severe systemic disease with definite functional limitation (e.g., unstable angina)
3. Any condition in which the respiratory centre and function are severely impaired or may become so
4. Asthmatic and allergic to non-steroidal anti-inflammatory drugs (NSAIDS)
5. Hypotension
6. Pregnancy and lactation
7. Recent head injury
8. Known hypersensitivity towards the active substance buprenorphine or to any of the excipients
9. Opioid-dependent patients, or patients in narcotic withdrawal treatment
9. Patients who are receiving monoamine oxidase (MAO) inhibitors or have taken them within the last two weeks
10. Patients suffering from myasthenia gravis
11. Patients suffering from delirium tremens or acute alcohol intoxication
12. Convulsive disorders
Date of first enrolment15/11/2007
Date of final enrolment30/10/2009

Locations

Countries of recruitment

  • United Kingdom
  • Wales

Study participating centre

North West Wales NHS Trust
Bangor
LL57 2PW
United Kingdom

Sponsor information

North West Wales NHS Trust (UK)
Hospital/treatment centre

c/o Dr. P. Birch
Ysbyty Gwynedd
Bangor
LL57 2PW
Wales
United Kingdom

Website http://www.northwestwales.org/
ROR logo "ROR" https://ror.org/04a496k07

Funders

Funder type

Government

North West Wales NHS Trust (UK) - Pathology Research Fund

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Basic results 21/04/2020 No No

Editorial Notes

21/04/2020: The following changes were made to the trial record:
1. Added clinicaltrialsregister.eu link to basic results (scientific).
2. The total final enrollment was added.
27/04/2016: No publications found, verifying study status with principal investigator